Development of sEH inhibitory vaccine for the treatment of cardiovascular diseases

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K17569
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: Saga University
• Principal Investigator: Shiraki Aya 佐賀大学, 医学部, 寄附講座教授 (50638252)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: EETｓ / ｓEH / ワクチン / 心筋梗塞

Outline of Final Research Achievements

We have developed an sEH vaccine that suppresses the function of the sEH protein in order to increase EETs in the body, a functional lipid produced by the body that has vasodilatory and anti-inflammatory effects. sEH protein is a protein that degrades EETs. We have confirmed that this vaccine causes the production of antibodies responsible for sEH inhibition in the bodies of mice, rats, and hamsters. We also found that when rats administered this vaccine suffered a myocardial infarction, it was less severe than in rats not administered the vaccine.

Free Research Field

循環器内科

Academic Significance and Societal Importance of the Research Achievements

血管や心臓にとって保護的に働くEETｓの作用を生かし、安価なワクチンで製剤化する試みは世界でも初めてのことです。ラットにおいて、心筋梗塞を軽くできる効果は期待できるものです。しかしながら、現在は動物実験の段階でありますので、今後ヒトに使用できるようになるまでには、ワクチンの配列の問題、アジュバント選択の問題、局所の腫れ、何回投与が必要なのか、などの問題や実際ヒトで効果があるのか確かめることなど乗り越えるべきハードルもあります。